


## Opiranserin

<b>Cat. No.:</b>	HY-109067
<b>CAS No.:</b>	1441000-45-8
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>34</sub> N <sub>2</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	394.51
<b>Target:</b>	GlyT; 5-HT Receptor; P2X Receptor
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling; GPCR/G Protein
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Opiranserin (VWZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC <sub>50</sub> s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC <sub>50</sub> =0.87 μM). Opiranserin is development as an injectable agent for the treatment of postoperative pain [1][2][3].		
<b>IC<sub>50</sub> &amp; Target</b>	5-HT <sub>2A</sub> Receptor 1.3 μM (IC <sub>50</sub> )	GlyT2 0.86 μM (IC <sub>50</sub> )	rP2X3 0.87 μM (IC <sub>50</sub> )

### REFERENCES

- [1]. Oh J, et al. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VWZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study. *J Clin Pharmacol*. 2018 Jan;58(1):64-73.
- [2]. Nedeljkovic SS, et al. Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VWZ-149 injections for postoperative pain following laparoscopic colorectal surgery. *BMJ Open*. 2017 Feb 17;7(2):e011035.
- [3]. Pang MH, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. *Drug Discov Today*. 2012 May;17(9-10):425-34.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA